Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...260261262263264265266267268269270...10661067»
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal, IO biomarker:  Cysteine protease of Clonorchis sinensis alleviates DSS-induced colitis in mice. (Pubmed Central) -  Sep 24, 2022   
    Both rCsCP and CsCA showed good therapeutic effects on the treatment of acute colitis, but rCsCP is a better choice. rCsCP is a safe, effective, readily available and promising therapeutic agent against IBD mainly by activating innate immunity and regulating the IL-12/IL-23r axis.
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation. (Pubmed Central) -  Sep 23, 2022   
    However, each antiemetic has unique adverse effects or interactions with specific drugs. Here, we review the literature relating to clinical trials on the prevention of CINV, and summarize the information to clarify the benefit of antiemetic regimens.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Isoorientin ameliorates OVA-induced asthma in a murine model of asthma. (Pubmed Central) -  Sep 23, 2022   
    A total of 30 C57BL/6 mice were randomly divided into five groups: control group, OVA group, Dex (dexamethasone, 10 mg/kg) group, low-dose Iso group (Iso-L, 25 mg/kg), and high-dose Iso group (Iso-H, 50 mg/kg)...The nuclear factor erythroid 2-like 2 (Nrf2) and HO-1 protein expression in Iso-L and Iso-H groups were enhanced over that in model group, while p-NF-κB-p65 and p-IκB-α protein expression was decreased (p < 0.05). Our research indicated that Iso alleviated the OVA-induced allergic asthma, and this effect can be explained by the modulation of Nrf2/HO-1 and NF-κB signaling pathway; thus, the results providing a therapeutic rationale for the treatment of Iso on allergic asthma.
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Dexamethasone/ Erector Spinae Plane Block Analgesia in Laparoscopic Cholecystectomy (clinicaltrials.gov) -  Sep 23, 2022   
    P2,  N=60, Not yet recruiting, 
    35579642. Trial completion date: Jan 2023 --> Jul 2023 | Initiation date: Jan 2022 --> Dec 2022 | Trial primary completion date: Jan 2023 --> Jul 2023
  • ||||||||||  dexamethasone injection / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date:  Dexamethasone for Migraine - Dose Comparison (clinicaltrials.gov) -  Sep 23, 2022   
    P4,  N=209, Active, not recruiting, 
    Trial completion date: Jan 2023 --> Jul 2023 | Initiation date: Jan 2022 --> Dec 2022 | Trial primary completion date: Jan 2023 --> Jul 2023 Recruiting --> Active, not recruiting | N=360 --> 209 | Trial completion date: Jul 2022 --> Dec 2022
  • ||||||||||  Xhance (fluticasone propionate intranasal spray) / OptiNose
    Product Theater 2 - Optinose : Optimizing Topical Treatment of Nasal Polyposis: Role of XHANCE in Stepped Care (Exhibit Hall (Upper Concourse), Kentucky International Convention Center) -  Sep 23, 2022 - Abstract #ACAAI2022ACAAI_553;    
    Description Identify key differentiating features of the Exhalation Delivery System™, reviewing efficacy and safety data for XHANCE. Discuss the treatment algorithm for nasal polyps, and use of XHANCE for: patients whose symptoms do not resolve with a standard nasal steroid spray; optimizing topical treatment before escalating care; and medical management post-surgery.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Trial completion date, Trial primary completion date:  Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma (clinicaltrials.gov) -  Sep 22, 2022   
    P1/2,  N=37, Recruiting, 
    Discuss the treatment algorithm for nasal polyps, and use of XHANCE for: patients whose symptoms do not resolve with a standard nasal steroid spray; optimizing topical treatment before escalating care; and medical management post-surgery. Trial completion date: Oct 2028 --> Oct 2029 | Trial primary completion date: Oct 2023 --> Oct 2024
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial completion date, Trial primary completion date:  Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty) (clinicaltrials.gov) -  Sep 22, 2022   
    P4,  N=132, Recruiting, 
    Trial completion date: Oct 2028 --> Oct 2029 | Trial primary completion date: Oct 2023 --> Oct 2024 Trial completion date: Jan 2023 --> May 2023 | Trial primary completion date: Jun 2022 --> May 2023
  • ||||||||||  Darzalex (daratumumab) / J&J, Ninlaro (ixazomib) / Takeda
    Trial completion date, Trial primary completion date:  Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis (clinicaltrials.gov) -  Sep 22, 2022   
    P1,  N=20, Recruiting, 
    Trial completion date: Jan 2023 --> May 2023 | Trial primary completion date: Jun 2022 --> May 2023 Trial completion date: Apr 2022 --> May 2023 | Trial primary completion date: Apr 2022 --> May 2023
  • ||||||||||  dexamethasone / Generic mfg., ropivacaine / Generic mfg., epinephrine / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Surgery:  Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries (clinicaltrials.gov) -  Sep 22, 2022   
    P4,  N=36, Completed, 
    Trial completion date: Apr 2022 --> May 2023 | Trial primary completion date: Apr 2022 --> May 2023 Unknown status --> Completed | N=220 --> 36 | Trial completion date: Sep 2021 --> Mar 2022 | Trial primary completion date: Sep 2020 --> Mar 2022
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Stress-level glucocorticoids increase fasting hunger and decrease cerebral blood flow in regions regulating eating. (Pubmed Central) -  Sep 22, 2022   
    From a clinical perspective, PMX-DHP is expected to become a first-line therapy to address unmet medical needs and prevent the exacerbation from moderate to severe ARDS (acute respiratory distress syndrome) in COVID-19 cases. Increased glucocorticoids at levels akin to those experienced during psychological stress, result in increased fasting hunger and decreased regional cerebral blood flow in a distinct brain network of prefrontal, emotional, reward, motivation, sensory and homeostatic regions that underlie control of food intake.
  • ||||||||||  hydrocortisone / Generic mfg.
    Preclinical, Journal:  Effect of Noni on Memory Impairment Induced by Hydrocortisone in Mice. (Pubmed Central) -  Sep 21, 2022   
    Furthermore, biochemical analyses showed that the activities of enzymes related to oxidative stress in the high-dose noni group were increased. Noni might be a powerful antioxidant that can protect nerve cells and may possess potential benefits for the treatment of memory impairment.
  • ||||||||||  dexamethasone / Generic mfg., fluticasone / Generic mfg.
    Journal:  Integrating an aerosolized drug delivery device with conventional static cultures and a dynamic airway barrier microphysiological system. (Pubmed Central) -  Sep 21, 2022   
    This work demonstrates a compact Surface Acoustic Wave (SAW) drug delivery device that generates an aerosol of respirable size for delivery of compounds directly onto polarized or differentiated epithelial cell cultures within an airway barrier MPS and conventional static inserts. As proof of principle, the SAW drug delivery device was used to nebulize viral dsRNA analog poly I:C and steroids fluticasone and dexamethasone without disrupting their biological function.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Analysis of drug efficacy for inflammatory skin on an organ-chip system. (Pubmed Central) -  Sep 21, 2022   
    After this pathological skin model was treated with dexamethasone and polyphyllin H, the results showed that polyphyllin H had a significant repair effect on the skin barrier and a significant inhibition effect on the release of inflammation-related cytokines, and the effects were more prominent than dexamethasone. This automated microfluidic system delivers an efficient tissue model for toxicological applications and drug evaluation for bacterial-infected damaged skin instead of animals.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Trial completion date, Trial primary completion date, Minimal residual disease:  The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study (clinicaltrials.gov) -  Sep 21, 2022   
    P2/3,  N=176, Recruiting, 
    The present study develops a cost-effective, biofriendly EVs-based glucocorticoid strategy for IgAN. Trial completion date: Jun 2031 --> Jun 2032 | Trial primary completion date: Jun 2030 --> Jun 2031
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial primary completion date:  Erector Spinae Plane Blocks for Adolescent Idiopathic Scoliosis (clinicaltrials.gov) -  Sep 21, 2022   
    P=N/A,  N=24, Enrolling by invitation, 
    Trial completion date: Jun 2031 --> Jun 2032 | Trial primary completion date: Jun 2030 --> Jun 2031 Trial completion date: Sep 2022 --> Jan 2023 | Trial primary completion date: Aug 2022 --> Jan 2023
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    Trial completion date, Trial primary completion date:  Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma (clinicaltrials.gov) -  Sep 21, 2022   
    P2,  N=55, Active, not recruiting, 
    Trial completion date: Sep 2022 --> Jan 2023 | Trial primary completion date: Aug 2022 --> Jan 2023 Trial completion date: Jan 2025 --> Apr 2025 | Trial primary completion date: Jan 2025 --> Apr 2025
  • ||||||||||  dexamethasone / Generic mfg.
    Journal, HEOR:  Burden of disease and survival rate amongst hospitalized newborns in Himalayan region in North India. (Pubmed Central) -  Sep 21, 2022   
    Only 993 inborn and 18 outborn received antenatal corticosteroids, with only 383 inborn and 4 outborn receiving four doses of Dexamethasone...Preterm accounts for a considerable majority of our total admissions. Greater efforts and investment in better prenatal care, infrastructure, therapeutic facilities, manpower, and periodic training and review of staff nurses are all urgently needed to address the extremely high burden of illnesses and mortality among hospitalized newborns; otherwise, lowering the NMR will remain an unattainable goal.
  • ||||||||||  prednisone / Generic mfg., hydrocortisone / Generic mfg.
    Retrospective data, Journal:  Adrenal Insufficiency among Children treated with Hormonal Therapy for Infantile Spasms. (Pubmed Central) -  Sep 21, 2022   
    This study highlights the necessity of hydrocortisone replacement therapy until AI has been excluded in a patient who has received hormonal therapy to treat infantile spasms. As such, routine laboratory assessment of adrenal function should be done in all patients.
  • ||||||||||  Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
    Review, Journal:  Immunobiology of neuromyelitis optica spectrum disorders. (Pubmed Central) -  Sep 21, 2022   
    Acute relapses are treated with IV methylprednisolone or plasma exchange. Recent advances on the NMOSD immunobiology led to approved treatments such as eculizumab, satralizumab, and inebilizumab.
  • ||||||||||  ciprofloxacin oral / Generic mfg., fluocinolone acetonide / Generic mfg.
    Clinical, PK/PD data, Journal:  Pharmacokinetics of ciprofloxacin and fluocinolone acetonide otic solution in pediatric patients. (Pubmed Central) -  Sep 21, 2022   
    Recent advances on the NMOSD immunobiology led to approved treatments such as eculizumab, satralizumab, and inebilizumab. These results demonstrated negligible systemic exposure to ciprofloxacin and fluocinolone acetonide following topical otic administration in pediatric patients with AOMT.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Diagnosis and Management of Adrenal Insufficiency and Adrenal Crisis in the Emergency Department. (Pubmed Central) -  Sep 21, 2022   
    These results demonstrated negligible systemic exposure to ciprofloxacin and fluocinolone acetonide following topical otic administration in pediatric patients with AOMT. Emergency clinicians must be prepared to recognize, evaluate, and manage those with known or suspected adrenal insufficiency or adrenal crisis.